华润三九医药股份有限公司关于公司产品通过谈判首次纳入国家医保目录的公告

Core Viewpoint - China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. has successfully negotiated to include its product Yiqi Qingfei Granules in the National Medical Insurance Directory (2025 version), which is expected to enhance the company's product portfolio in the respiratory field and strengthen its market position [1][3]. Product Information - Product Name: Yiqi Qingfei Granules - Drug Classification Code: ZA09G - Drug Type: Traditional Chinese Medicine (TCM) - Registration Category: TCM Class 3.2 - Dosage Form: Granules - Agreement Validity: January 1, 2026, to December 31, 2027 - Indications: Used for symptoms related to Qi and Yin deficiency, spleen deficiency, and dampness, including fatigue, shortness of breath, dry cough, and gastrointestinal discomfort [1][2]. Impact on the Company - Yiqi Qingfei Granules received its drug registration certificate from the National Medical Products Administration in January 2025 and is currently undergoing post-market academic promotion and sales activities. The inclusion in the National Medical Insurance Directory is expected to have a positive impact on the company's product layout in the respiratory field, although it is not anticipated to significantly affect short-term operating performance [3].